Showing 1041-1050 of 1576 results for "".
- Bio-Tissue Expands National Footprint, Ramps Up Sales Force by More than 25 Percenthttps://modernod.com/news/bio-tissue-expands-national-footprint-ramps-up-sales-force-by-more-than-25-percent-2/2476882/Bio-Tissue, a TissueTech company, announced the expansion of its sales force to more effectively meet the needs of clinicians and their patients. “A growing body of scientific evidence has cemented CAM as a mainstay treatment for ocular surface diseases,” Grady Grant III, TissueTech Vice P
- Bio-Tissue Expands National Footprint, Ramps Up Sales Force by More than 25 Percenthttps://modernod.com/news/bio-tissue-expands-national-footprint-ramps-up-sales-force-by-more-than-25-percent/2479535/Bio-Tissue, a subsidiary of TissueTech, announced the expansion of its sales force to more effectively meet the needs of clinicians and their patients. “A growing body of scientific evidence has cemented CAM as a mainstay treatment for ocular surface diseases,” Grady Grant III, TissueTech
- Pioneering Ophthalmologist William J. Lahners Passes Awayhttps://modernod.com/news/pioneering-ophthalmologist-william-j-lahners-passes-away/2480517/William J. Lahners, MD, FACS, Medical Director, Center for Sight, in Sarasota, Florida, passed away on Friday at the age of 53.
- NextGen Healthcare Expands Eye Care Solutions Through Strategic Alignment with Eyefinityhttps://modernod.com/news/nextgen-healthcare-expands-eye-care-solutions-through-strategic-alignment-with-eyefinity/2484213/NextGen Healthcare said it is enhancing its suite of offerings for optometrists and ophthalmologists through a new alignment with Eyefinity, a VSP Vision company. According to NextGen, the new collaboration will d
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- DORC Announces Strategic Partnership With WEFIS for Research and Development of Ophthalmic Instrumentshttps://modernod.com/news/dorc-announces-strategic-partnership-with-wefis-for-research-and-development-of-ophthalmic-instruments/2480584/DORC International and WEFIS GmbH have announced a strategic partnership based on an equity investment by DORC. The partnership will focus on research and development aimed at improving performance, efficiency, and usability of cataract surgery instruments. Financial terms of the d
- Gentex Announces Partnership With eSight To Develop Next Generation Digital Eyewearhttps://modernod.com/news/gentex-announces-partnership-with-esight-to-develop-next-generation-digital-eyewear/2480538/Gentex announced that it is partnering with eSight, provider of vision enhancement technology, to develop and manufacture the next generation of mobile electronic eyewear designed to help people living with visual impairments. Terms of the d
- Is Undergraduate Ophthalmology Teaching in the United Kingdom Still Fit for Purpose?https://modernod.com/news/is-undergraduate-ophthalmology-teaching-in-the-united-kingdom-still-fit-for-purpose/2479479/An editorial in the publication Eye examines the reasons behind why an increasing number of junior doctors and general practitioners in the UK are losing confidence in their ophthalmic knowledge. Such factors cited in the d
- Glaucoma UK Launches New Services Booklet for People Living With Glaucomahttps://modernod.com/news/glaucoma-uk-launches-new-services-booklet-for-people-living-with-glaucoma/2478926/Glaucoma UK is launching a new booklet to highlight the services it can offer to people with glaucoma, and the health care professionals looking after them. With an estimated 700,000 people in the UK living with the d
- Conbercept Treatment of Wet AMD Completes 36-Week Primary Endpoint Visits of Phase 3 Trialhttps://modernod.com/news/conbercept-treatment-of-wet-amd-completes-36-week-primary-endpoint-visits-of-phase-3-trial/2478698/China-based Chengdu Kanghong Pharmaceutical Group announced a key development milestone of its key product conbercept last month. Kanghong is seeking global approval of conbercept by undertaking a multicenter, multinational, d